Beaverton, Oregon-based company signs agreement with Smith Kline & French to develop Epitope's proprietary compounds for the treatment of protozoan-caused diseases, including malaria. In return for funding animal and human clinical trials and the purchase of an equity position in Epitope, SK&F receives exclusive world-wide marketing rights except in the U.S., where the drugs will be co-marketed.
You may also be interested in...
Hanmi showcases at JPM its contract production capabilities for COVID-19 vaccines as South Korea prepares to bring in candidates from several global developers, while LG Chem highlights progress across multiple pipeline projects.
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker
Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.